Back to SYRE
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC → SYRE
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC SYRE Position History
Spyre Therapeutics, Inc. • Healthcare
Quarters held
27
Latest value
$468K
Q3 2026
Peak value
$30.7M
First seen
Q4 2025
Dollar value over time
Show data table
| Period | Position value |
|---|---|
| Q4 2025 | $20K |
| Q4 2025 | $124K |
| Q4 2025 | $1.9M |
| Q1 2026 | $79K |
| Q1 2026 | $192K |
| Q1 2026 | $9.9M |
| Q1 2026 | $92K |
| Q1 2026 | $96K |
| Q1 2026 | $81K |
| Q2 2026 | $139K |
| Q2 2026 | $3.3M |
| Q2 2026 | $27.8M |
| Q2 2026 | $260K |
| Q2 2026 | $365K |
| Q2 2026 | $29K |
| Q2 2026 | $161K |
| Q2 2026 | $13.4M |
| Q2 2026 | $911K |
| Q3 2026 | $2M |
| Q3 2026 | $2.9M |
| Q3 2026 | $30.7M |
| Q3 2026 | $260K |
| Q3 2026 | $366K |
| Q3 2026 | $29K |
| Q3 2026 | $162K |
| Q3 2026 | $18.8M |
| Q3 2026 | $468K |
Quarter-by-quarter history
Every disclosed snapshot of the position
| Quarter | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|
| Q3 2026 | $468K | 5.3K | — | — |
| Q3 2026 | $18.8M | 210.8K | — | — |
| Q3 2026 | $162K | 1.8K | — | — |
| Q3 2026 | $29K | 327 | — | — |
| Q3 2026 | $366K | 4.1K | — | — |
| Q3 2026 | $260K | 2.9K | — | — |
| Q3 2026 | $30.7M | 344.8K | — | — |
| Q3 2026 | $2.9M | 32.1K | — | — |
| Q3 2026 | $2M | 22.4K | — | — |
| Q2 2026 | $911K | 10.3K | — | — |
| Q2 2026 | $13.4M | 150.8K | — | — |
| Q2 2026 | $161K | 1.8K | — | — |
| Q2 2026 | $29K | 327 | — | — |
| Q2 2026 | $365K | 4.1K | — | — |
| Q2 2026 | $260K | 2.9K | — | — |
| Q2 2026 | $27.8M | 313.4K | — | — |
| Q2 2026 | $3.3M | 36.8K | — | — |
| Q2 2026 | $139K | 1.6K | — | — |
| Q1 2026 | $81K | 1.6K | — | — |
| Q1 2026 | $96K | 1.9K | — | — |
| Q1 2026 | $92K | 1.8K | — | — |
| Q1 2026 | $9.9M | 196.6K | — | — |
| Q1 2026 | $192K | 3.8K | — | — |
| Q1 2026 | $79K | 1.6K | — | — |
| Q4 2025 | $1.9M | 57.8K | — | — |
| Q4 2025 | $124K | 3.8K | — | — |
| Q4 2025 | $20K | 596 | — | — |
Other funds holding SYRE
$809.9M
$795.4M
$430.1M
$383.5M
$377.5M
$348.1M
$336.7M